KURA — Kura Oncology Inc
NASDAQ · Healthcare · Biotechnology
$13.05
+$0.16 (+1.24%)
Kura Oncology Inc (KURA) is a biotechnology company listed on NASDAQ. It is led by Troy Edward Wilson J.D., Ph.D., based in 4930 Directors Place, San Diego, CA, United States, 92121, with about 260 employees. Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Latest reported KURA revenue for 2025-09-30 was $20.8M. Net income was -$74.1M. Revenue was up 35.7% from 2025-06-30 to 2025-09-30. KURA currently screens at market cap $861.1M.
Use this KURA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KURA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KURA SEC filings page. Lician reads the product cache first so this HTML stays unique to Kura Oncology Inc even when a live quote feed is slow.
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
KURA Key Statistics
Market Cap
$861.12M
Volume
5.32M
Previous Close
$12.40
Day Range
$12.85 – $13.90
P/B Ratio
7.74
EPS
-$2.02
Revenue
$53.88M
Net Income
-$173.98M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-322.9%
Employees
260
KURA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $53.88M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$173.98M | -$152.63M | -$135.84M | -$130.47M |
| EPS (Diluted) | -$2.02 | -$2.08 | -$2.03 | -$1.97 |
Total Assets
$760.16M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$224.46M
Operating Cash Flow
$134.32M
Free Cash Flow
$0.00
Kura Oncology Inc Company Information
- Chairman, CEO & President
- Troy Edward Wilson J.D., Ph.D.
- Headquarters
- 4930 Directors Place, San Diego, CA, United States, 92121
- Website
- kuraoncology.com
- Phone
- 858 500 8800
- IPO / Founded
- 2015-09-22
- Sector
- Healthcare
- Industry
- Biotechnology